MedTrace Logo

Purified Exosome Product (PEP) Injected Into the Hypodermis

NCT06429033 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2025-12-26

No results posted yet for this study

Summary

This clinical trial aims to characterize the safety, tolerability, and histological profile of PEP (Purified Exosome Product) when injected into the hypodermis of healthy adults. The main questions this study aims to answer are:

Is PEP safe and tolerable when injected into the hypodermis of healthy adults?

Subjects will serve as their own control and researchers will compare PEP to Control to see if PEP is safe.

Conditions

  • Safety

Interventions

DRUG

PEP (Purified Exosome Product)

Injection of PEP into hypodermis of abdomen

Sponsors & Collaborators

  • Clinical Testing of Beverly Hills

    lead OTHER

Principal Investigators

  • John H Joseph, MD · Clinical Testing Center

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-04-14
Primary Completion
2025-12-17
Completion
2025-12-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06429033 on ClinicalTrials.gov